
Sixera initiates its first clinical trial on SXR1096 in Netherton Syndrome
with the potential to be the first available treatment of the rare and serious skin disease Netherton syndrome Stockholm, December 7, 2021. The Swedish biotech
with the potential to be the first available treatment of the rare and serious skin disease Netherton syndrome Stockholm, December 7, 2021. The Swedish biotech
Welcome to our newly launched website were we will make it possible for you to follow our work and take part of insights from our
If you have any question or want to know more about us please contact us.